Psychedelic Group Therapy

Group psychotherapy has a long history within mainstream psychotherapeutic traditions, and many established group formats (psychoanalytic groups, encounter groups, self-help groups) have accumulated evidence of usefulness. By contrast, psychedelic-assisted therapies have largely been delivered in individual one-to-one formats in modern clinical research, leaving open whether and how psychedelics can be administered safely and effectively within group settings. The author notes a scarcity of contemporary, evidence-based data on psychedelic group therapy and recognises common professional concerns about safety, disturbance of other participants, and how to support individual inner processes in a group. This article reports a practice-based account of legally authorised psychedelic group therapy conducted in Switzerland under the Swiss Federal Office for Public Health’s compassionate use permissions between 2016 and February 2020. Rather than presenting a controlled trial, the paper aims to describe the structure, practical procedures, participant selection considerations and the authors’ experiential observations from these group workshops, and to situate them within historical and contemporary practice contexts.

The material presented is an experiential and practice-oriented account derived from a compassionate use programme rather than a randomised trial. Treatments were authorised on an individual basis by the Swiss Federal Office for Public Health (BAG) for patients who had previously undergone other psychotherapies or pharmacotherapies with insufficient benefit. The programme ran from 2016 until February 2020 and comprised four group workshops per year, with group sizes typically ranging from 5 to 13 patients. Each participant had specific permission for one substance (mostly LSD or MDMA during the period reported); psilocybin was not yet available in this programme before 2020. Workshops used a three-day structure modelled on earlier SÄPT training formats: an evening preparatory meeting (day 1) with mindfulness, breathing exercises, nonverbal contact exercises and a short sharing round; a full drug day (day 2) in which oral intake occurred around 10:00, followed by an extended period of monitored inward-focused experience and later moderated interaction; and an integration/sharing day (day 3) to verbalise and process the experience. Therapies were delivered by teams of three therapists (two lead psychiatrists/psychotherapists plus a female co-therapist) with rotating lead roles for the sharing rounds. MDMA dosing was standardised at 125 mg and LSD doses generally ranged from 100 μg to 200 μg. Participants were encouraged to remain inward-directed during the initial hours of drug action; guided presence, reassurance, brief touch and occasional low-intensity interventions were used as needed. Music and silence were balanced (approximately one-third music, two-thirds silence), and participants did not use headphones or eyeshades. Eligibility reflected general contraindications for psychedelic treatment (risk of psychotic decompensation, severe personality disorder, acute suicidal crisis) together with additional suitability assessments for group participation; examples cited include exclusion or careful consideration for individuals with Asperger’s disorder who are overwhelmed by group situations or people with visual impairment who expressed concerns about orientation under LSD. The authors note that BAG initially required demonstration of safety in small groups (first group of three) before permitting larger groups. Procedures included advising participants to write a personal report soon after the workshop and integrating group sessions with ongoing individual psychotherapy. Where available, the authors reference a comparison study (Schmid et al.) that assessed acute LSD effects using the 5D-ASC (Altered States of Consciousness) questionnaire between patients in group therapy (n = 11) and healthy volunteers in individual settings (n = 40).

The paper reports predominantly practice-derived observations and a small body of comparative psychometric data rather than formal efficacy outcomes from controlled trials. Historical data from SÄPT (1988–1993) are summarised: nearly 200 patients received mostly group-based psychedelic treatments during that period, typically embedded within ongoing individual psychotherapy (average of seven psychedelic sessions over three years and approximately 70 individual talking sessions), and a follow-up investigation suggested "surprisingly good" outcomes, though the extracted text does not provide quantitative outcome metrics or standardised effect sizes. From the compassionate use programme (2016–Feb 2020), the authors describe operational details and safety experience: across the reported workshops there were no accounts of chaotic, unmanageable sessions in the regulated, therapeutically oriented setting. Patient narratives included in the paper illustrate common experiential themes—initial apprehension about group participation that shifted to feelings of connectedness, relief and appreciation after sharing and integration. Selected brief excerpts reflect this trajectory: one participant wrote that she would not have wanted to miss the mutual sharing of experiences and felt "proud and grateful" that she participated; another trainee described a transition from exclusion and fear to a state of ‘‘pure being’’ and connectedness. The authors also report that some group members met outside workshops as part of integration, which the team viewed positively. Comparative psychometric findings cited from Schmid and collaborators show that acute LSD effects on the 5D-ASC were broadly similar between patients in compassionate-use group therapy (n = 11) and healthy volunteers in individual research settings (n = 40). However, certain subscales differed: visionary restructuring (VR) scores were significantly greater in healthy subjects receiving 200 μg LSD compared with patients (p < 0.05). Ratings for audio-visual synaesthesia, changed meaning of percepts and blissful state were higher after 200 μg LSD in healthy subjects compared with patients (p < 0.05), and those ratings were also higher for 200 μg versus 100 μg LSD in healthy subjects (p < 0.01). The authors contrast the relative safety in regulated therapeutic groups with reports from unregulated underground settings: they cite two deaths and multiple hospitalisations in an underground Berlin workshop in 2009 linked to substance mixing and overdosing, and a large ambulance response in Handeloh, Germany in 2015 after an overdose of an unknown substance at an underground gathering. The extracted text does not provide systematic adverse-event counts or standardised safety rates for the Swiss programme beyond these narrative statements.

Barkowski and colleagues place their observations in the context of a long anthropological history of communal ingestion of mind-altering substances and the well-established benefits of group psychotherapy more generally. They report mostly positive anecdotal and practice-based impressions from the Swiss compassionate use groups but emphasise that these data fall short of rigorous scientific evidence, noting that modern research into psychedelic group therapy is still in its infancy and that most published controlled work dates from the 1950s and 1960s. The authors argue that the Swiss compassionate use framework provides a valuable pragmatic avenue to treat severely ill patients outside standardised trial protocols and to gather preliminary data on disorders that remain under-researched (examples mentioned include obsessive–compulsive disorder, cluster headache, gambling and PTSD). They also raise an economic argument: because psychedelic sessions require prolonged therapeutic presence (several hours), a group format could improve cost-effectiveness by distributing therapist time across multiple patients, but this potential benefit depends on demonstrating safety and efficacy in scientific studies. Methodological challenges are discussed candidly. The authors acknowledge that the randomised, placebo-controlled trial is the legal and scientific gold standard for developing prescribable medicines, but they highlight the particular difficulty of effective blinding with highly psychoactive drugs and report evidence of near-complete unblinding in a pilot LSD study where patients and therapists correctly guessed allocation in almost all sessions. Consequently, Barkowski and colleagues call for methodological innovation that spans both drug research and psychotherapy research traditions, stressing that psychedelic group therapy requires hybrid approaches to properly evaluate risks and benefits. They conclude that sound methodological development and contemporary clinical research are necessary to determine the safety and efficacy of psychedelic group therapy.